Drug intelligence / Profile preview

BMS-650032 + peginterferon alfa-2a + ribavirin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral, Subcutaneous

Overview

BMS-650032 + peginterferon alfa-2a + ribavirin is a triple combination regimen developed for the treatment of chronic hepatitis C virus (HCV) infection, particularly targeting genotype 1. - BMS-650032 (asunaprevir) is an orally administered small molecule inhibitor of the HCV NS3/4A serine protease, essential for viral replication[5][9]. - Peginterferon alfa-2a is a pegylated interferon that stimulates immune response and exhibits antiviral effects[2][6][4]. - Ribavirin is a nucleoside analog with broad antiviral activity that acts synergistically with interferon-based therapies[2][4][6]. This combination has been investigated for enhanced sustained virologic response rates and overcoming resistance observed with dual therapy, especially in patients who did not previously respond to standard-of-care regimens[1][3][9].

Other names: asunaprevir + peginterferon alfa-2a + ribavirin

Targets

NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)IFNAR (Immune system modulation via type I interferon receptor)HCV RNA (Hepatitis C virus RNA)

Beyond the preview

Go deeper on BMS-650032 + peginterferon alfa-2a + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-650032 + peginterferon alfa-2a + ribavirin.

Explore the full profile